Lurasidone Non-Interventional Study in Schizophrenia Patients

Angelini Pharma

Status: Completed

Conditions: Schizophrenia

Treatments: Drug: Lurasidone

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06527885

153(A)IM21322

Details and patient eligibility

About

The study is a multicentric, national, non-interventional, prospective, single arm study.

The main goal of this study is to gather information about the effects, in a real-life setting, of lurasidone treatment on patient's reported outcomes, in terms of patient's treatment satisfaction, Quality of Life and functioning changes after 6 weeks from lurasidone treatment initiation in schizophrenia patients naïve to lurasidone.

Full description

Important aim of the study is to investigate, aspects related to effectiveness, safety and tolerability at 3 months' lurasidone treatment in a routine practice in Italian clinical settings.

Only patients with primary diagnosis of schizophrenia who are prescribed lurasidone was evaluated for inclusion in the study.

Enrollment: 61 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (≥18 years) male or female subjects;
• Primary diagnosis of schizophrenia
• Patients not previously treated with lurasidone. The choice to initiate lurasidone treatment is independent of being included in the study;
• Patients legally capable of giving their written consent for participation in the study and for personal data processing.

Exclusion criteria

• Concomitant participation in a clinical trial

Trial design

61 participants in 1 patient group

Lurasidone Treatment

Description:

Adult patients suffering from schizophrenia treated for 3 months with lurasidone according to routine clinical practice.

Treatment:

Drug: Lurasidone